Camarillo, CA (April 11, 2023) – PBS Biotech, an innovative, single-use bioreactor manufacturer and process development services provider, announces its collaboration with denovoMATRIX, a leading supplier of next-gen biomimetic coating technologies. By joining forces, PBS Biotech and denovoMATRIX seek to foster xeno-free expansion and scale-up of clinical-grade mesenchymal stromal cells (MSCs) and induced pluripotent stem cells (iPSCs) for use in allogeneic and autologous cell and gene therapies. The first outcome of this collaboration is a white paper presenting the advantages in MSC manufacturing that can be achieved using their cutting-edge technologies.
PBS Biotech teamed up with denovoMATRIX to address the clear market need for materials and methods that enable the production of a clinically relevant yield of therapeutic cells through safe and efficient manufacturing processes. Biomimetic matrices, isoMATRIX, myMATRIX MSC, and beadMATRIX in tandem with PBS Vertical-Wheel® bioreactors, were used for the culture of MSCs and resulted in high isolation efficiency as well as robust cell proliferation. In their first whitepaper (available here), denovoMATRIX and PBS Biotech demonstrated a drastic improvement in final cell yield and/or reduction in manufacturing time for MSCs. ‘’We are thrilled to see the leverage created by our collaboration with PBS Biotech in addressing MSC manufacturing challenges with such clear results.’’ said Dr. Dejan Hušman, CEO of denovoMATRIX. As a result of the success of this initial study, the teams at PBS Biotech and denovoMATRIX plan to address iPSC manufacturing next by introducing a novel 3D production system for large-scale manufacturing of iPSCs.
The Bioprocess R&D team at PBS Biotech is experienced in developing robust, efficient, and scalable processes using Vertical-Wheel bioreactors for internal development and contracted process development projects for clients. “denovoMATRIX matrices provide the industry with a safer alternative to traditional blood-derived attachment factors, which will enable our clients to advance to the next phase of development faster.” said Sunghoon Jung, Sr. Director of Bioprocess R&D. “We are very excited to combine our expertise in cell culture engineering and process development to provide guidance to the industry and look forward to sharing the results of our iPSC study with you in the coming months.”
ABOUT PBS BIOTECH
PBS Biotech, Inc. is a leading manufacturer of single-use bioreactor systems and provider of process development services for the global cell therapy market. PBS’ bioreactors utilize proprietary Vertical-Wheel® technology to create homogeneous and scalable mixing conditions for a variety of therapeutic products and cell culture applications. PBS Biotech’s vision is to become the world’s standard manufacturing platform for allogeneic cell therapies. To learn more, visit pbsbiotech.com.
denovoMATRIX GmbH deploys a modular, biomimetic coating technology to enable high performance cell culture, bringing cell therapies to patients and accelerating the path to market for cultivated meat. The company leverages chemical synthesis, stem cell biology and design thinking to build a platform of biomaterials, which addresses major life science challenges. By providing both cell-based therapy and cultivated meat companies with solutions, denovoMATRIX is at the forefront of innovation in cell manufacturing processes. For more information, visit denovomatrix.com.